Title:
HCV-DERIVED POLYPEPTIDES AND USES THEREOF
Document Type and Number:
WIPO Patent Application WO/2010/106509
Kind Code:
A3
Abstract:
The present invention relates to Hepatitis C virus (HCV)-derived polypeptides and nucleic acid molecules encoding same which advantageously comprises a cd81 -binding region. In this connection, the present invention specifically relates to the use of the polypeptides or nucleic acid molecules in compositions and methods for the prevention, the treatment and the diagnosis of HCV infections.
More Like This:
Inventors:
KREY THOMAS (FR)
REY FELIX A (FR)
KIKUTI CARLOS MASSAYUKI (FR)
DAMIER-PIOLLE LAURENCE (FR)
REY FELIX A (FR)
KIKUTI CARLOS MASSAYUKI (FR)
DAMIER-PIOLLE LAURENCE (FR)
Application Number:
PCT/IB2010/051158
Publication Date:
December 29, 2010
Filing Date:
March 17, 2010
Export Citation:
Assignee:
PASTEUR INSTITUT (FR)
CENTRE NAT RECH SCIENT (FR)
KREY THOMAS (FR)
REY FELIX A (FR)
KIKUTI CARLOS MASSAYUKI (FR)
DAMIER-PIOLLE LAURENCE (FR)
CENTRE NAT RECH SCIENT (FR)
KREY THOMAS (FR)
REY FELIX A (FR)
KIKUTI CARLOS MASSAYUKI (FR)
DAMIER-PIOLLE LAURENCE (FR)
International Classes:
A61K38/16; A61P31/14; C07K14/18
Domestic Patent References:
| WO2006039326A2 | 2006-04-13 | |||
| WO2008022401A1 | 2008-02-28 | |||
| WO2008108918A1 | 2008-09-12 |
Other References:
MCCAFFREY K ET AL: "Expression and Characterization of a Minimal Hepatitis C Virus Glycoprotein E2 Core Domain that Retains CD81 Binding", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US LNKD- DOI:10.1128/JVI.02782-06, vol. 81, no. 17, 1 September 2007 (2007-09-01), pages 9584 - 9590, XP008104648, ISSN: 0022-538X, [retrieved on 20070620]
DRUMMER HEIDI E ET AL: "A conserved Gly(436)-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry", JOURNAL OF VIROLOGY, vol. 80, no. 16, August 2006 (2006-08-01), pages 7844 - 7853, XP007913245, ISSN: 0022-538X
FLINT M ET AL: "CHARACTERIZATION OF HEPATITIS C VIRUS E2 GLYCOPROTEIN INTERACTION WITH A PUTATIVE CELLULAR RECEPTOR, CD81", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 73, no. 8, 1 August 1999 (1999-08-01), pages 6235 - 6244, XP002940624, ISSN: 0022-538X
GROLLO LARA ET AL: "Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes", ANTIVIRAL THERAPY, MTM PUBLICATIONS, LONDON, GB, vol. 11, no. 8, 1 January 2006 (2006-01-01), pages 1005 - 1014, XP009102499, ISSN: 1359-6535
OWSIANKA ANIA ET AL: "Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US LNKD- DOI:10.1128/JVI.79.17.11095-11104.2005, vol. 79, no. 17, 1 September 2005 (2005-09-01), pages 11095 - 11104, XP002394551, ISSN: 0022-538X
KREY THOMAS ET AL: "The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule.", PLOS PATHOGENS 2010 LNKD- PUBMED:20174556, vol. 6, no. 2, 2010, pages E1000762, XP007913219, ISSN: 1553-7374
WHIDBY JILLIAN ET AL: "Blocking Hepatitis C Virus Infection with Recombinant Form of Envelope Protein 2 Ectodomain", JOURNAL OF VIROLOGY, vol. 83, no. 21, November 2009 (2009-11-01), pages 11078 - 11089, XP007913230
FENOUILLET EMMANUEL ET AL: "Contribution of redox status to hepatitis C virus E2 envelope protein function and antigenicity", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, no. 39, September 2008 (2008-09-01), pages 26340 - 26348, XP007913228, ISSN: 0021-9258
DRUMMER HEIDI E ET AL: "A conserved Gly(436)-Trp-Leu-Ala-Gly-Leu-Phe-Tyr motif in hepatitis C virus glycoprotein E2 is a determinant of CD81 binding and viral entry", JOURNAL OF VIROLOGY, vol. 80, no. 16, August 2006 (2006-08-01), pages 7844 - 7853, XP007913245, ISSN: 0022-538X
FLINT M ET AL: "CHARACTERIZATION OF HEPATITIS C VIRUS E2 GLYCOPROTEIN INTERACTION WITH A PUTATIVE CELLULAR RECEPTOR, CD81", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 73, no. 8, 1 August 1999 (1999-08-01), pages 6235 - 6244, XP002940624, ISSN: 0022-538X
GROLLO LARA ET AL: "Exploiting information inherent in binding sites of virus-specific antibodies: design of an HCV vaccine candidate cross-reactive with multiple genotypes", ANTIVIRAL THERAPY, MTM PUBLICATIONS, LONDON, GB, vol. 11, no. 8, 1 January 2006 (2006-01-01), pages 1005 - 1014, XP009102499, ISSN: 1359-6535
OWSIANKA ANIA ET AL: "Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein", JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US LNKD- DOI:10.1128/JVI.79.17.11095-11104.2005, vol. 79, no. 17, 1 September 2005 (2005-09-01), pages 11095 - 11104, XP002394551, ISSN: 0022-538X
KREY THOMAS ET AL: "The disulfide bonds in glycoprotein E2 of hepatitis C virus reveal the tertiary organization of the molecule.", PLOS PATHOGENS 2010 LNKD- PUBMED:20174556, vol. 6, no. 2, 2010, pages E1000762, XP007913219, ISSN: 1553-7374
WHIDBY JILLIAN ET AL: "Blocking Hepatitis C Virus Infection with Recombinant Form of Envelope Protein 2 Ectodomain", JOURNAL OF VIROLOGY, vol. 83, no. 21, November 2009 (2009-11-01), pages 11078 - 11089, XP007913230
FENOUILLET EMMANUEL ET AL: "Contribution of redox status to hepatitis C virus E2 envelope protein function and antigenicity", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 283, no. 39, September 2008 (2008-09-01), pages 26340 - 26348, XP007913228, ISSN: 0021-9258
Attorney, Agent or Firm:
CABINET ORES (Paris, FR)
Download PDF: